Photocure ASA ( (PHCUF) ) has issued an announcement.
Photocure ASA has announced the publication of the BRAVO study, which highlights the clinical benefits of Blue Light Cystoscopy (BLC) in reducing the risk of bladder cancer recurrence. The study, conducted in a real-world setting, demonstrates a 38% reduction in recurrence risk for non-muscle invasive bladder cancer patients using BLC compared to traditional white light cystoscopy. These findings support the use of BLC in clinical practice to enhance treatment decisions and improve patient outcomes, aligning with existing guidelines and previous clinical trial results.
More about Photocure ASA
Photocure ASA, known as the Bladder Cancer Company, is focused on delivering transformative solutions to improve the lives of bladder cancer patients. Their unique technology involves making cancer cells glow bright pink, which has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange.
YTD Price Performance: -18.80%
Average Trading Volume: 388
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $133.6M
For detailed information about PHCUF stock, go to TipRanks’ Stock Analysis page.